HR Execs on the Move

Muse bio

www.musebio.com

 
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.musebio.com
  • 4001 Discovery Dr Suite N321, UCB 027
    Boulder, CO USA 80309

Executives

Name Title Contact Details
Tanya Lipscomb
Chief Technology Officer, Vice President of Research and Development Profile
Kevin Ness
Chief Executive Officer Profile

Similar Companies

Triplet Therapeutics

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.

BioHiTech

BioHitech America is the industry leader in the development of a simple, cost-effective food waste disposal technology designed to solve today’s landfill diversion and sustainability objectives. The Eco-Safe Digester handles food waste at the point of generation, no residual food waste to store or transport. The Eco-Safe Digester can convert up to 2,400 pounds of food waster per day into a nutrient-neutral grey water that can safely be disposed of via municipal sewer systems. The Eco-Safe Digester saves money by avoiding disposal costs and significantly reduces greenhouse gas emissions by providing a sustainable means of transportation for the waste by-product with doesn’t require on-road transportation. The Eco-Safe Digester’s cloud-based management solution is designed to measure and collect food waste data. It correlates information to report cost savings and environmental reductions as well as communicate opportunities to prevent waste altogether. This modifiable data can also be used to assess the performance of your staff and predict trends for smarter budgeting and purchasing purposes. In addition to diverting food waste from landfills and converting food waste into a resource, the machine is now poised for significant growth in this emerging data-driven zero waste initiative climate because it identifies waste in order to prevent the creation of it all together. Already implemented in many applications across the globe, the Eco-Safe Digester is ideal for use in any food service, hospitality, healthcare, government, conference center, education center, or stadium that generates a high volume of waste.

Joyn Bio

Probiotics for Plants, We design microbes for more sustainable agriculture.

Nano Mark

Nano Mark, Llc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.